Featured Research

from universities, journals, and other organizations

Early success of anti-HIV preventive oral drug regimen is promising, but questions remain

Date:
March 14, 2011
Source:
Mary Ann Liebert, Inc./Genetic Engineering News
Summary:
The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50 percent reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert Inc.

The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis (PrEP) can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert, Inc.

After the success of a trial of PrEP in a high risk population of men who have sex with men (MSM), expanded studies are set to begin that will enroll more than 20,000 men and women. Although PrEP, composed of a two-drug regimen (the oral antiretroviral agents tenofovir and emtricitabine), was shown to be safe and effective in early clinical testing, Gavin Myers, MA and Kenneth Mayer, MD, Alpert Medical School of Brown University (Providence, RI) emphasize the need for more research in several key areas: the need for ongoing PrEP clinical monitoring of side effects; the diminished preventive benefits seen in patients who do not adhere to the PrEP regimen and the need for counseling; the attitudes and awareness of physicians who would be prescribing PrEP; and the potential for intermittent PrEP to be as effective as once-daily dosing. They discuss these issues in the article, "Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings."

"This is an extraordinary example of translational medicine in the service of HIV prevention. But implementation faces major social obstacles. Adherence to a PreP regimen is key. And the cost of the drugs may make it impractical for all but the highest at-risk populations," says Jeffrey Laurence, MD, Editor-in-Chief of the Journal and Director of the Laboratory for AIDS Virus Research at Weill Medical College of Cornell University (New York, NY).


Story Source:

The above story is based on materials provided by Mary Ann Liebert, Inc./Genetic Engineering News. Note: Materials may be edited for content and length.


Journal Reference:

  1. Gavin M. Myers, Kenneth H. Mayer. Oral Preexposure Anti-HIV Prophylaxis for High-Risk U.S. Populations: Current Considerations in Light of New Findings. AIDS Patient Care and STDs, 2011; 25 (2): 63 DOI: 10.1089/apc.2010.0222

Cite This Page:

Mary Ann Liebert, Inc./Genetic Engineering News. "Early success of anti-HIV preventive oral drug regimen is promising, but questions remain." ScienceDaily. ScienceDaily, 14 March 2011. <www.sciencedaily.com/releases/2011/03/110314132256.htm>.
Mary Ann Liebert, Inc./Genetic Engineering News. (2011, March 14). Early success of anti-HIV preventive oral drug regimen is promising, but questions remain. ScienceDaily. Retrieved April 23, 2014 from www.sciencedaily.com/releases/2011/03/110314132256.htm
Mary Ann Liebert, Inc./Genetic Engineering News. "Early success of anti-HIV preventive oral drug regimen is promising, but questions remain." ScienceDaily. www.sciencedaily.com/releases/2011/03/110314132256.htm (accessed April 23, 2014).

Share This



More Health & Medicine News

Wednesday, April 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Big Pharma Braces for M&A Wave

Big Pharma Braces for M&A Wave

Reuters - Business Video Online (Apr. 22, 2014) Big pharma on the move as Novartis boss, Joe Jimenez, tells Reuters about plans to transform his company via an asset exchange with GSK, and Astra Zeneca shares surge on speculation that Pfizer is looking for a takeover. Joanna Partridge reports. Video provided by Reuters
Powered by NewsLook.com
Study Says Most Crime Not Linked To Mental Illness

Study Says Most Crime Not Linked To Mental Illness

Newsy (Apr. 22, 2014) A new study finds most crimes committed by people with mental illness are not caused by symptoms of their illness or disorder. Video provided by Newsy
Powered by NewsLook.com
Hagel Gets Preview of New High-Tech Projects

Hagel Gets Preview of New High-Tech Projects

AP (Apr. 22, 2014) Defense Secretary Chuck Hagel is given hands-on demonstrations Tuesday of some of the newest research from DARPA _ the military's Defense Advanced Research Projects Agency program. (April 22) Video provided by AP
Powered by NewsLook.com
How Smaller Plates And Cutlery Could Make You Feel Fuller

How Smaller Plates And Cutlery Could Make You Feel Fuller

Newsy (Apr. 22, 2014) NBC's "Today" conducted an experiment to see if changing the size of plates and utensils affects the amount individuals eat. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins